FDA Approved: RISPERDAL M-TAB — Supplemental Application (Janssen Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved Janssen's supplemental application for RISPERDAL M-TAB (risperidone), resulting in updated labeling or expanded indications for the formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• RISPERDAL M-TAB (Risperidone)

Snippet

SUPPL AP for RISPERDAL M-TAB (RISPERIDONE)